TME Alteration in HER2 Positive Breast Cancer
NCT06533670 · Status: ACTIVE_NOT_RECRUITING · Type: OBSERVATIONAL · Enrollment: 30
Last updated 2026-01-28
Summary
Evaluate for changes in the tumor microenvironment before/during neoadjuvant chemotherapy and after treatment in patients diagnosed with HER2-positive advanced breast cancer and receiving neoadjuvant cancer therapy and surgery for curative purposes.
Conditions
- Breast Cancer
- HER2-positive Breast Cancer
- Chemotherapy Effect
Sponsors & Collaborators
-
Seoul National University Hospital
lead OTHER
Eligibility
- Min Age
- 18 Years
- Sex
- ALL
- Healthy Volunteers
- No
Timeline & Regulatory
- Start
- 2024-07-19
- Primary Completion
- 2026-07-19
- Completion
- 2026-07-19
Countries
- South Korea
Study Locations
More Related Trials
-
microRNA of Human Epidermal Growth Factor Receptor 2 （HER2）Positive Patient Treated With Herceptin
NCT02656589 ·Status: UNKNOWN
-
Impact of Immuno-Oncologic Agent on Neoadjuvant Chemotherapy in Triple Negative Breast Cancer
NCT05910710 ·Status: RECRUITING
-
Monitoring Response to Neoadjuvant Chemotherapy in HER2 Negative Breast Cancer Using High-speed MR Spectroscopic Imaging
NCT03568448 ·Status: ACTIVE_NOT_RECRUITING
-
Predicting Long-Term Clinical Outcomes in Chinese Breast Cancer Patients Receiving Neoadjuvant Chemotherapy
NCT06856616 ·Status: ACTIVE_NOT_RECRUITING
-
Genetic Alteration After Systemic Treatment in Breast Cancer
NCT02591966 ·Status: UNKNOWN
-
Gut Microbiome Components Predict Response to Neoadjuvant Therapy in HER2-positive Breast Cancer Patients : A Prospective Study
NCT05444647 ·Status: UNKNOWN
-
Molecular Imaging of HER2 Expression in Breast Cancer Using [99mTc]Tc-G3-(G3S)3C Before Chemo/Targeted Therapy
NCT05923268 ·Status: COMPLETED ·Phase: NA
-
A Study of Patients With HER2-Positive Metastatic Breast Cancer
NCT00105456 ·Status: COMPLETED
-
Assessing Treatment Response in Breast Cancer With Functional Imaging
NCT02688257 ·Status: COMPLETED
-
Real-World Data on First-line Treatment of Hormone Receptor-positive, HER2-negative, Metastatic Breast Cancer in Brazil
NCT05034393 ·Status: COMPLETED
-
MRD in High-risk EBC
NCT06566729 ·Status: ACTIVE_NOT_RECRUITING
-
Dynamic Monitoring of HER2 and ctDNA Specific Mutations in Patients With Recurrent or Metastatic Breast Cancer by Digital PCR
NCT03947736 ·Status: UNKNOWN
-
Evaluation of Treatment Efficacy by Circulating Tumor Cell Phenotype Surveillance in Breast Cancer Patients
NCT05326295 ·Status: RECRUITING
-
Microbiome Immunotherapy Neoadjuvant Assessment
NCT06709651 ·Status: RECRUITING
-
Treatment Intermittent Periods Based on ctDNA-MRD（Circulating Tumor DNA-minimal Residual Disease） Status in Advanced HER2-Positive Breast Cancer
NCT07132502 ·Status: NOT_YET_RECRUITING
-
Prognostic Value of Biomarkers in HR + / HER2 - Advanced Breast Cancer
NCT04683770 ·Status: UNKNOWN
-
What Factors Affect Breast Cancer Neoadjuvant Chemotherapy Efficacy?
NCT03501394 ·Status: UNKNOWN ·Phase: NA
-
Comparative Expression of ER,PR and HER2/Neu in Initial and Recurrent Breast Cancer.
NCT07056205 ·Status: ENROLLING_BY_INVITATION
-
Prospective Cohort Study of Breast Cancer Patients Treated With Radiotherapy
NCT04203849 ·Status: ENROLLING_BY_INVITATION
-
HER2-positive Breast Cancer Registry
NCT06603597 ·Status: RECRUITING
-
Tumor-microenvironment Spatial Interaction to Identify Markers of Resistance to Therapy in HER2+ Breast Cancer Patients
NCT06518382 ·Status: RECRUITING
-
Predictive Value of Tumor Vascular Normalization Scoring in HER-2 Positive Breast Cancer
NCT06868758 ·Status: ACTIVE_NOT_RECRUITING
-
To Evaluate the Characteristics of a Breast Cancer
NCT01055678 ·Status: WITHDRAWN ·Phase: EARLY_PHASE1
-
The Association Between Plasma Metabolites and the Risk, Efficacy and Prognosis in Early Breast Cancer
NCT06698679 ·Status: RECRUITING
-
Impact of Neoadjuvant Chemotherapy on the Peripheral Blood Immune Phenotype in Operable Breast Cancer
NCT04897009 ·Status: ACTIVE_NOT_RECRUITING